Almond Consumption and Risk Factors for Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

被引:49
作者
Lee-Bravatti, Michelle A. [1 ]
Wang, Jifan [1 ]
Avendano, Esther E. [2 ]
King, Ligaya [1 ]
Johnson, Elizabeth J. [3 ]
Raman, Gowri [2 ]
机构
[1] Tufts Univ, Friedman Sch Nutr & Policy, Boston, MA 02111 USA
[2] Tufts Med Ctr, Tufts Clin Evidence Synth Ctr, Boston, MA 02111 USA
[3] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA
关键词
systematic review; meta-analysis; blood lipids; risk factors; metabolic syndrome; hypertension; hyperglycemia; hypercholesterolemia; obesity; CORONARY-HEART-DISEASE; NUT CONSUMPTION; DIETARY; WEIGHT; LIPIDS; LIPOPROTEINS; ADULTS; DEATH; WOMEN;
D O I
10.1093/advances/nmz043
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Evidence suggests that eating nuts may reduce the risk of cardiovascular disease (CVD). We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating almond consumption and risk factors for CVD. MEDLINE, Cochrane Central, Commonwealth Agricultural Bureau, and previous systematic reviews were searched from 1990 through June 2017 for RCTs of >= 3 wk duration that evaluated almond compared with no almond consumption in adults who were either healthy or at risk for CVD. The most appropriate stratum was selected with an almond dose closer to 42.5 g, with a control most closely matched for macronutrient composition, energy intake, and similar intervention duration. The outcomes included risk factors for CVD. Random-effects model meta-analyses and subgroup meta-analyses were performed. Fifteen eligible trials analyzed a total of 534 subjects. Almond intervention significantly decreased total cholesterol (summary net change: -10.69 mg/dL; 95% CI: -16.75, -4.63 mg/dL), LDL cholesterol (summary net change: -5.83 mg/dL; 95% CI: -9.91, -1.75 mg/dL); body weight (summary net change: -1.39 kg; 95% CI: -2.49, -0.30 kg), HDL cholesterol (summary net change: -1.26 mg/dL; 95% CI: -2.47, -0.05 mg/dL), and apolipoprotein B (apoB) (summary net change: -6.67 mg/dL; 95% CI: -12.63, -0.72 mg/dL). Triglycerides, systolic blood pressure, apolipoprotein A1, high-sensitivity C-reactive protein, and lipoprotein (a) showed no difference between almond and control in the main and subgroup analyses. Fasting blood glucose, diastolic blood pressure, and body mass index significantly decreased with almond consumption of >42.5 g compared with <= 42.5 g. Almond consumption may reduce the risk of CVD by improving blood lipids and by decreasing body weight and apoB. Substantial heterogeneity in eligible studies regarding almond interventions and dosages precludes firmer conclusions.
引用
收藏
页码:1076 / 1088
页数:13
相关论文
共 39 条
  • [1] Abazarfard Z, 2014, J RES MED SCI, V19, P457
  • [2] Review of nut phytochemicals, fat-soluble bioactives, antioxidant components and health effects
    Alasalvar, Cesarettin
    Bolling, Bradley W.
    [J]. BRITISH JOURNAL OF NUTRITION, 2015, 113 : S68 - S78
  • [3] Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study
    Albert, CM
    Gaziano, JM
    Willett, WC
    Manson, JE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (12) : 1382 - 1387
  • [4] [Anonymous], ANN REP ALM ALM
  • [5] [Anonymous], FULL REP ALL NUTR 12
  • [6] Effects of Daily Almond Consumption on Cardiometabolic Risk and Abdominal Adiposity in Healthy Adults With Elevated LDL-Cholesterol: A Randomized Controlled Trial
    Berryman, Claire E.
    West, Sheila G.
    Fleming, Jennifer A.
    Bordi, Peter L.
    Kris-Etherton, Penny M.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (01):
  • [7] Almond ingestion at mealtime reduces postprandial glycemia and chronic ingestion reduces hemoglobin A1c in individuals with well-controlled type 2 diabetes mellitus
    Cohen, Ashley E.
    Johnston, Carol S.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (09): : 1312 - 1317
  • [8] Crossover study of diets enriched with virgin olive oil, walnuts or almonds. Effects on lipids and other cardiovascular risk markers
    Damasceno, N. R. T.
    Perez-Heras, A.
    Serra, M.
    Cofan, M.
    Sala-Vila, A.
    Salas-Salvado, J.
    Ros, E.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2011, 21 : S14 - S20
  • [9] METAANALYSIS IN CLINICAL-TRIALS
    DERSIMONIAN, R
    LAIRD, N
    [J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188
  • [10] Obesity and heart disease - A statement for healthcare professionals from the Nutrition Committee, American Heart Association
    Eckel, RH
    [J]. CIRCULATION, 1997, 96 (09) : 3248 - 3250